Clinical Consequences of the Lipophilicity and Plasma Protein Binding of Antiarrhythmic Drugs and Active Metabolites in Man
- 16 December 1984
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 432 (1), 45-56
- https://doi.org/10.1111/j.1749-6632.1984.tb14507.x
Abstract
In two series of antiarrhythmic drugs tested, as the octanol/water partition coefficient increases so do the following: elimination from the body by biotransformation, first-pass biotransformation in the liver and gastrointestinal tract after oral administration, protein binding to some extent, and penetration into brain tissue. Patients receiving lipophilic beta-adrenoreceptor blocking drugs may experience more central nervous system side effects than those receiving hydrophilic beta blockers. Structural modification of a drug, guided by the concept of bioisosterism, may allow the disassociation of therapeutic from toxic activities. Alpha-1 acid glycoprotein is the major plasma protein that binds the basic antiarrhythmic drugs. Antiarrhythmic drug metabolites are generally more polar (less lipophilic) and less plasma protein-bound than the parent drugs.This publication has 18 references indexed in Scilit:
- Atenolol and TimololNew England Journal of Medicine, 1982
- Pharmacokinetics of Metoprolol in Patients with Hepatic CirrhosisClinical Pharmacokinetics, 1981
- The clinical importance of cardioselectivity and lipophilicity in beta blockersAmerican Heart Journal, 1980
- Long‐Term Clinical Experience with Atenolol—a New Selective β‐1‐Blocker with Few Side‐Effects from the Central Nervous SystemActa Medica Scandinavica, 1979
- Decreased first-pass metabolism of labetalol in chronic liver disease.BMJ, 1978
- The Influence of Cirrhosis on Steady-State Blood Concentrations of Unbound Propranolol after Oral Administration1Clinical Pharmacokinetics, 1978
- Antiarrhythmic activity of p-hydroxy-N-(2-diethylaminoethyl)benzamide (the p-hydroxy isostere of procainamide) in dogs and miceJournal of Medicinal Chemistry, 1977
- Clinical Pharmacokinetics of β-Adrenoreceptor Blocking DrugsClinical Pharmacokinetics, 1976
- Plasma and Tissue Protein Binding of Drugs in PharmacokineticsDrug Metabolism Reviews, 1976
- ??-Adrenergic Receptor Blocking Drugs in HypertensionDrugs, 1974